Form 8-K - Current report:
SEC Accession No. 0001493152-24-043615
Filing Date
2024-11-05
Accepted
2024-11-05 07:39:41
Documents
15
Period of Report
2024-11-04
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 52431
2 ex99-1.htm EX-99.1 9399
  Complete submission text file 0001493152-24-043615.txt   288086

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ptix-20241104.xsd EX-101.SCH 3796
4 XBRL DEFINITION FILE ptix-20241104_def.xml EX-101.DEF 30062
5 XBRL LABEL FILE ptix-20241104_lab.xml EX-101.LAB 36749
6 XBRL PRESENTATION FILE ptix-20241104_pre.xml EX-101.PRE 27085
18 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5651
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 (212) 994-8200
Protagenic Therapeutics, Inc.\new (Filer) CIK: 0001022899 (see all company filings)

EIN.: 061390025 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12555 | Film No.: 241425645
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)